title: Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy.
abstract: BACKGROUND
  Most patients with chronic heart failure (CHF) receive the same dose of angiotensin-converting enzyme (ACE) inhibitors because there is currently no measure of treatment efficacy. We sought to determine whether titration of vasodilator therapy according to plasma brain natriuretic peptide (BNP) concentration may be of value in the individual optimization of vasodilator therapy in CHF.
  
  
  RESULTS
  Twenty patients with mild to moderate CHF receiving stable conventional therapy including an ACE inhibitor were randomly assigned to titration of ACE inhibitor dosage according to serial measurement of plasma BNP concentration (BNP group) or optimal empirical ACE inhibitor therapy (clinical group) for 8 weeks. Only the BNP-driven approach was associated with significant reductions in plasma BNP concentration throughout the duration of the study and a significantly greater suppression when compared with empiric therapy after 4 weeks [-42.1% (-58.2, -19.7) vs -12.0% (-31.8, 13.8), P =.03]. Both treatment strategies were well tolerated and associated with favorable neurohormonal and hemodynamic effects; however, in comparison between groups, mean heart rate fell (P =.02) and plasma renin activity rose (P =.03) in the BNP group when compared with the clinical group.
  
  
  CONCLUSIONS
  Plasma BNP concentration may be chronically reduced by tailored vasodilator therapy in CHF. Furthermore, titration of vasodilator therapy according to plasma BNP was associated with more profound inhibition of the renin-angiotensin-aldosterone system and significant fall in heart rate when compared with empiric therapy.
authors.affiliation: Clinical Research Initiative in Heart Failure, West Medical Building, University of Glasgow, Scotland. drm2x@udcf.gla.ac.uk
authors.forename: D R
authors.initials: DR
authors.lastname: Murdoch
authors.forename: T A
authors.initials: TA
authors.lastname: McDonagh
authors.forename: J
authors.initials: J
authors.lastname: Byrne
authors.forename: L
authors.initials: L
authors.lastname: Blue
authors.forename: R
authors.initials: R
authors.lastname: Farmer
authors.forename: J J
authors.initials: JJ
authors.lastname: Morton
authors.forename: H J
authors.initials: HJ
authors.lastname: Dargie
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D002908:Chronic Disease; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D012084:Renin-Angiotensin System / Q000187:drug effects; D016037:Single-Blind Method; D017186:Titrimetry; D014665:Vasodilator Agents / Q000008:administration & dosage*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D014665:Vasodilator Agents; D020097:Natriuretic Peptide, Brain